KR102913965B1 - 비근육 침습성 방광암 치료 시의 파클리탁셀-히알루론산 접합체 - Google Patents
비근육 침습성 방광암 치료 시의 파클리탁셀-히알루론산 접합체Info
- Publication number
- KR102913965B1 KR102913965B1 KR1020217007729A KR20217007729A KR102913965B1 KR 102913965 B1 KR102913965 B1 KR 102913965B1 KR 1020217007729 A KR1020217007729 A KR 1020217007729A KR 20217007729 A KR20217007729 A KR 20217007729A KR 102913965 B1 KR102913965 B1 KR 102913965B1
- Authority
- KR
- South Korea
- Prior art keywords
- paclitaxel
- treatment
- prodrug
- pharmaceutical composition
- hyaluronic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
- C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
- C08B37/0072—Hyaluronic acid, i.e. HA or hyaluronan; Derivatives thereof, e.g. crosslinked hyaluronic acid (hylan) or hyaluronates
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L5/00—Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
- C08L5/08—Chitin; Chondroitin sulfate; Hyaluronic acid; Derivatives thereof
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Polymers & Plastics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Materials Engineering (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT102018000009731 | 2018-10-25 | ||
| IT102018000009731A IT201800009731A1 (it) | 2018-10-25 | 2018-10-25 | Coniugato paclitaxel - acido ialuronico nel trattamento del carcinoma vescicale non infiltrante |
| PCT/IB2019/059073 WO2020084525A1 (en) | 2018-10-25 | 2019-10-23 | Paclitaxel-hyaluronic acid conjugate in the treatment of non-muscle invasive bladder cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20210083249A KR20210083249A (ko) | 2021-07-06 |
| KR102913965B1 true KR102913965B1 (ko) | 2026-01-16 |
Family
ID=65324453
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020217007729A Active KR102913965B1 (ko) | 2018-10-25 | 2019-10-23 | 비근육 침습성 방광암 치료 시의 파클리탁셀-히알루론산 접합체 |
Country Status (21)
| Country | Link |
|---|---|
| US (4) | US20200397909A1 (https=) |
| EP (1) | EP3870233B1 (https=) |
| JP (1) | JP7518815B2 (https=) |
| KR (1) | KR102913965B1 (https=) |
| CN (2) | CN112805035A (https=) |
| CA (1) | CA3112188A1 (https=) |
| DK (1) | DK3870233T3 (https=) |
| EA (1) | EA202190614A1 (https=) |
| ES (1) | ES2971217T3 (https=) |
| FI (1) | FI3870233T3 (https=) |
| HR (1) | HRP20240188T1 (https=) |
| HU (1) | HUE066288T2 (https=) |
| IT (1) | IT201800009731A1 (https=) |
| LT (1) | LT3870233T (https=) |
| MA (1) | MA63879B1 (https=) |
| PL (1) | PL3870233T3 (https=) |
| PT (1) | PT3870233T (https=) |
| RS (1) | RS65193B1 (https=) |
| SI (1) | SI3870233T1 (https=) |
| SM (1) | SMT202400021T1 (https=) |
| WO (1) | WO2020084525A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT202000007747A1 (it) * | 2020-04-10 | 2021-10-10 | Fidia Farm Spa | Coniugato acido ialuronico-paclitaxel nel trattamento del mesotelioma |
| IT202000008209A1 (it) * | 2020-04-17 | 2021-10-17 | Fidia Farm Spa | Procedimento di sintesi di un coniugato acido ialuronico-paclitaxel |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004035629A2 (en) | 2002-10-18 | 2004-04-29 | Fidia Farmaceutici S.P.A. | Taxanes covalently bounded to hyaluronic acid or hyaluronic acid derivatives |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0138572B1 (en) | 1983-10-11 | 1990-07-25 | FIDIA S.p.A. | Hyaluronic acid fractions having pharmaceutical activity, methods for preparation thereof, and pharmaceutical compositions containing the same |
| IT1263393B (it) | 1993-07-30 | 1996-08-05 | Fidia Advanced Biopolymers Srl | Processo per la preparazione e purificazione di acido ialuronico ad alto peso molecolare |
| NZ516873A (en) | 2001-02-12 | 2003-11-28 | Warner Lambert Co | Compositions containing retinoids and erb inhibitors and their use in inhibiting retinoid skin damage |
| AR047938A1 (es) * | 2003-08-25 | 2006-03-15 | Combinatorx Inc | Formulaciones, conjugados y combinaciones de farmacos para el tratamiento de neoplasmas |
| ITMI20071267A1 (it) | 2007-06-22 | 2008-12-23 | Fidia Farmaceutici | Uso di coniugati dell'acido ialuronico nel trattamento locale di malattie cutanee iperproliferative |
| IT1402384B1 (it) | 2010-09-09 | 2013-09-04 | Fidia Farmaceutici | Processo per la produzione di acido ialuronico in escherichia coli o bacillus megaterium |
| IT1402385B1 (it) | 2010-09-09 | 2013-09-04 | Fidia Farmaceutici | Processo per la produzione di acido ialuronico in escherichia coli o bacillus subtilis |
| EP3290511B1 (en) | 2011-11-09 | 2020-08-26 | Spinalcyte, LLC | Dermal fibroblasts for treatment of degenerative disc disease |
| IT201600079633A1 (it) | 2016-07-28 | 2018-01-28 | Fidia Farm Spa | Procedimento di preparazione e purificazione del sale sodico dell’acido ialuronico |
| CN110859962B (zh) | 2019-11-25 | 2021-01-22 | 山东大学 | 巴比妥酸衍生物修饰的二硫化钼二维纳米材料及其应用 |
-
2018
- 2018-10-25 IT IT102018000009731A patent/IT201800009731A1/it unknown
-
2019
- 2019-10-23 CA CA3112188A patent/CA3112188A1/en active Pending
- 2019-10-23 PT PT198016305T patent/PT3870233T/pt unknown
- 2019-10-23 ES ES19801630T patent/ES2971217T3/es active Active
- 2019-10-23 LT LTEPPCT/IB2019/059073T patent/LT3870233T/lt unknown
- 2019-10-23 WO PCT/IB2019/059073 patent/WO2020084525A1/en not_active Ceased
- 2019-10-23 FI FIEP19801630.5T patent/FI3870233T3/fi active
- 2019-10-23 EA EA202190614A patent/EA202190614A1/ru unknown
- 2019-10-23 PL PL19801630.5T patent/PL3870233T3/pl unknown
- 2019-10-23 HR HRP20240188TT patent/HRP20240188T1/hr unknown
- 2019-10-23 JP JP2021515655A patent/JP7518815B2/ja active Active
- 2019-10-23 KR KR1020217007729A patent/KR102913965B1/ko active Active
- 2019-10-23 RS RS20240122A patent/RS65193B1/sr unknown
- 2019-10-23 SI SI201831054T patent/SI3870233T1/sl unknown
- 2019-10-23 MA MA63879A patent/MA63879B1/fr unknown
- 2019-10-23 CN CN201980064603.9A patent/CN112805035A/zh active Pending
- 2019-10-23 US US16/959,979 patent/US20200397909A1/en not_active Abandoned
- 2019-10-23 DK DK19801630.5T patent/DK3870233T3/da active
- 2019-10-23 CN CN202510138513.7A patent/CN119792555A/zh active Pending
- 2019-10-23 HU HUE19801630A patent/HUE066288T2/hu unknown
- 2019-10-23 EP EP19801630.5A patent/EP3870233B1/en active Active
- 2019-10-23 SM SM20240021T patent/SMT202400021T1/it unknown
-
2021
- 2021-03-17 US US17/204,183 patent/US20210196833A1/en not_active Abandoned
- 2021-05-10 US US17/315,962 patent/US12465649B2/en active Active
-
2023
- 2023-12-14 US US18/539,827 patent/US20240123077A1/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004035629A2 (en) | 2002-10-18 | 2004-04-29 | Fidia Farmaceutici S.P.A. | Taxanes covalently bounded to hyaluronic acid or hyaluronic acid derivatives |
Non-Patent Citations (2)
| Title |
|---|
| Journal of Urology, 2011, 185, 445-449. |
| Urologic oncology: Seminars and original investigations, 2013, 31, 1261-1269. |
Also Published As
| Publication number | Publication date |
|---|---|
| CN119792555A (zh) | 2025-04-11 |
| SI3870233T1 (sl) | 2024-03-29 |
| US20210268119A1 (en) | 2021-09-02 |
| EP3870233A1 (en) | 2021-09-01 |
| PL3870233T3 (pl) | 2024-05-06 |
| EA202190614A1 (ru) | 2021-06-03 |
| DK3870233T3 (da) | 2024-02-05 |
| US20200397909A1 (en) | 2020-12-24 |
| US12465649B2 (en) | 2025-11-11 |
| ES2971217T3 (es) | 2024-06-04 |
| SMT202400021T1 (it) | 2024-03-13 |
| JP2022503771A (ja) | 2022-01-12 |
| CN112805035A (zh) | 2021-05-14 |
| CA3112188A1 (en) | 2020-04-30 |
| FI3870233T3 (fi) | 2024-02-07 |
| JP7518815B2 (ja) | 2024-07-18 |
| KR20210083249A (ko) | 2021-07-06 |
| RS65193B1 (sr) | 2024-03-29 |
| HRP20240188T1 (hr) | 2024-05-10 |
| US20210196833A1 (en) | 2021-07-01 |
| EP3870233B1 (en) | 2023-12-06 |
| IT201800009731A1 (it) | 2020-04-25 |
| PT3870233T (pt) | 2024-02-01 |
| MA63879B1 (fr) | 2024-02-29 |
| LT3870233T (lt) | 2024-02-26 |
| US20240123077A1 (en) | 2024-04-18 |
| WO2020084525A1 (en) | 2020-04-30 |
| HUE066288T2 (hu) | 2024-07-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4704753B2 (ja) | ヒアルロン酸又はヒアルロン酸誘導体に共有結合したタキサン類 | |
| CN107669632B (zh) | 药物载体、胶束、药物制剂、及其制备方法和用途 | |
| CA2713813C (en) | Intralymphatic chemotherapy drug carriers | |
| Luo et al. | Multifunctional composite nanoparticles based on hyaluronic acid-paclitaxel conjugates for enhanced cancer therapy | |
| US20240123077A1 (en) | Paclitaxel-hyaluronic acid conjugate in the treatment of non-muscle invasive bladder cancer | |
| WO2010106169A1 (en) | Optical imaging agents | |
| CN115667214A (zh) | 包括药物二聚体的纳米颗粒及其用途 | |
| US20200276183A1 (en) | Pharmaceutical compositions comprising imiquimod for use in the treatment of carcinoma in situ of the bladder | |
| WO2019210414A1 (en) | Fucan-based compounds and complexes | |
| Sun et al. | Polysaccharide hydrogels regulate macrophage polarization and enhance the anti-tumor efficacy of melanoma | |
| US9962469B2 (en) | Adhesion-preventing preparation comprising composition comprising polycationic triblock copolymer and polyanionic polymer | |
| Lian et al. | Rational design of hybrid nanomicelles integrating mucosal penetration and P-glycoprotein inhibition for efficient oral delivery of paclitaxel | |
| US20250345457A1 (en) | Functionalized diblock copolymer and its preparation method and application | |
| KR102162774B1 (ko) | 커큐민 유도체 함유 pH 민감성 블록 공중합체를 유효성분으로 포함하는 염증성 질환의 예방, 개선 또는 치료용 조성물 | |
| HK40048954B (en) | Paclitaxel-hyaluronic acid conjugate in the treatment of non-muscle invasive bladder cancer | |
| HK40048954A (en) | Paclitaxel-hyaluronic acid conjugate in the treatment of non-muscle invasive bladder cancer | |
| CN112142986A (zh) | 一种官能化双嵌段共聚物及其制备方法和用途 | |
| EA043782B1 (ru) | Конъюгат паклитаксела и гиалуроновой кислоты в лечении мышечно-неинвазивного рака мочевого пузыря | |
| JPWO2005037292A1 (ja) | 糖鎖含有キトサン誘導体を含有する内視鏡手術用粘膜下膨隆液組成物 | |
| KR20150099655A (ko) | 벤조일옥시신남알데히드-폴리에틸렌글리콜 결합 마이셀에 아연 프로토포르피린을 담지한 pH 감응형 항암 전구약물 및 이의 제조방법 | |
| WO2019195728A1 (en) | Refillable drug delivery by affinity homing | |
| CN117122695A (zh) | 一种靶向活化cd44分子的透明质酸功能化偶联物及制备方法和应用 | |
| EP2489351A1 (en) | Inclusion complex of deoxypodophyllotoxin of cyclodextrin, preparation method, use for treament of cancer thereof | |
| Zhu | Nanoparticles Targeting Tumour Associated Macrophages | |
| Hou et al. | Tumor Microenvironment-Responsive Ternary Nanosystem for Enhanced Antitumor and Antimetastasis Efficacy Against Breast Cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| A201 | Request for examination | ||
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PA0201 | Request for examination |
St.27 status event code: A-1-2-D10-D11-exm-PA0201 |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
St.27 status event code: A-1-2-D10-D21-exm-PE0902 |
|
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| D22 | Grant of ip right intended |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D22-EXM-PE0701 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| PE0701 | Decision of registration |
St.27 status event code: A-1-2-D10-D22-exm-PE0701 |
|
| F11 | Ip right granted following substantive examination |
Free format text: ST27 STATUS EVENT CODE: A-2-4-F10-F11-EXM-PR0701 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| PR0701 | Registration of establishment |
St.27 status event code: A-2-4-F10-F11-exm-PR0701 |
|
| PR1002 | Payment of registration fee |
St.27 status event code: A-2-2-U10-U12-oth-PR1002 Fee payment year number: 1 |
|
| U12 | Designation fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U12-OTH-PR1002 (AS PROVIDED BY THE NATIONAL OFFICE) Year of fee payment: 1 |
|
| PG1601 | Publication of registration |
St.27 status event code: A-4-4-Q10-Q13-nap-PG1601 |
|
| Q13 | Ip right document published |
Free format text: ST27 STATUS EVENT CODE: A-4-4-Q10-Q13-NAP-PG1601 (AS PROVIDED BY THE NATIONAL OFFICE) |